6th Edition of Global Conference on
Addiction Medicine, Behavioral Health and Psychiatry
October 20-22, 2025 | Orlando, Florida, USA
Carbamazepine
This drug is used to treat epilepsy and diseases that induce seizures because it contains anticonvulsant characteristics. It is the medication that is prescribed in oral dose forms available including chewable tablets, immediate-release tablets, extended-release tablets, and extended-release capsules. There is also an intravenous (IV) form available. It is also a generic medication. Oftentimes, generic drugs are less expensive than name brands. The brand-name medicine may not always be available in every dose form or strength. Schizophrenia is also treated with it in combination with several medications. It is furthermore used as a second-line drug for the treatment of the bipolar disorder. Some common side effects of carbamazepine include constipation, tiredness, drowsiness, and disorders of voluntary movement.
Nile Stanley
University of North Florida, United States
Ann Marie Leonard Zabel
Curry College, United States
Denis Larrivee
University of Navarra, Spain
Scharbach Hugues
Paris University, France
Alphonsus Obayuwana
Triple-H Project LLC, United States
Malasri Chaudhery Malgeri
Recovery com, United States
Jana Furstova
Palacký University Olomouc, Czech RepublicSubmit your abstract Today
Title : Tailoring biblio-poetry therapies using AI and biofeedback for addiction treatment
Nile Stanley, University of North Florida, United States
Title : The A-B-C of happiness coaching
Alphonsus Obayuwana, Triple-H Project LLC, United States
Title : Clinical pharmacology of marijuana: Update 2024
Frederick J Goldstein, Philadelphia College of Osteopathic Medicine, United States
Title : Trait-based recovery: Evidence-based trait activation to reduce depression, anxiety, and improve client engagement in addiction treatment
Jason Glenn Roop, The Center for Trait-Based Transformation, United States
Title : An investigation of the factors responsible for ubstance abuse from a cognitive perspective based on a mixed method approach
Adewole Olukorede, Literary Edifice, Italy
Title : A Long-Acting Naltrexone Implant (for Opioid Use Disorder: First-in-Human Phase I Trial)
Steven M Cohen, Akyso Therapeutics, United States